CARLSBAD, Calif. (AP) _ GenMark Diagnostics Inc. (GNMK) on Thursday reported a loss of $11.6 million in its fourth quarter.
On a per-share basis, the Carlsbad, California-based company said it had a loss of 21 cents.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
The molecular diagnostics company posted revenue of $19.4 million in the period, beating Street forecasts. Four analysts surveyed by Zacks expected $19.2 million.
For the year, the company reported that its loss narrowed to $50.5 million, or 91 cents per share. Revenue was reported as $70.8 million.
GenMark Diagnostics expects full-year revenue in the range of $85 million to $90 million.
GenMark Diagnostics shares have increased 40 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.82, an increase of 53 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GNMK at https://www.zacks.com/ap/GNMK